Citation
Kim, Ji Yeun, et al. "Immune Responses to the ChAdOx1 nCoV-19 and BNT162b2 Vaccines and to Natural Coronavirus Disease 2019 Infections Over a 3-Month Period." The Journal of Infectious Diseases, vol. 225, no. 5, 2022, pp. 777-784.
Kim JY, Lim SY, Park S, et al. Immune Responses to the ChAdOx1 nCoV-19 and BNT162b2 Vaccines and to Natural Coronavirus Disease 2019 Infections Over a 3-Month Period. J Infect Dis. 2022;225(5):777-784.
Kim, J. Y., Lim, S. Y., Park, S., Kwon, J. S., Bae, S., Park, J. Y., Cha, H. H., Seo, M. H., Lee, H. J., Lee, N., Kim, K., Shum, D., Jee, Y., & Kim, S. H. (2022). Immune Responses to the ChAdOx1 nCoV-19 and BNT162b2 Vaccines and to Natural Coronavirus Disease 2019 Infections Over a 3-Month Period. The Journal of Infectious Diseases, 225(5), 777-784. https://doi.org/10.1093/infdis/jiab579
Kim JY, et al. Immune Responses to the ChAdOx1 nCoV-19 and BNT162b2 Vaccines and to Natural Coronavirus Disease 2019 Infections Over a 3-Month Period. J Infect Dis. 2022 03 2;225(5):777-784. PubMed PMID: 34850034.
TY - JOUR
T1 - Immune Responses to the ChAdOx1 nCoV-19 and BNT162b2 Vaccines and to Natural Coronavirus Disease 2019 Infections Over a 3-Month Period.
AU - Kim,Ji Yeun,
AU - Lim,So Yun,
AU - Park,Soonju,
AU - Kwon,Ji-Soo,
AU - Bae,Seongman,
AU - Park,Ji Young,
AU - Cha,Hye Hee,
AU - Seo,Mi Hyun,
AU - Lee,Hyun Jung,
AU - Lee,Nakyung,
AU - Kim,Kideok,
AU - Shum,David,
AU - Jee,Youngmee,
AU - Kim,Sung-Han,
PY - 2021/10/14/received
PY - 2021/11/23/accepted
PY - 2021/12/2/pubmed
PY - 2022/3/29/medline
PY - 2021/12/1/entrez
KW - BNT162b2
KW - COVID-19
KW - ChAdOx1 nCoV-19
KW - T cells
KW - antibody
KW - second dose
SP - 777
EP - 784
JF - The Journal of infectious diseases
JO - J Infect Dis
VL - 225
IS - 5
N2 - BACKGROUND: There are limited data directly comparing immune responses to vaccines and to natural infections with coronavirus disease 2019 (COVID-19). This study assessed the immunogenicity of the BNT162b2 and ChAdOx1 nCoV-19 vaccines over a 3-month period and compared the immune responses with those to natural infections. METHOD: We enrolled healthcare workers who received BNT162b2 or ChAdOx1 nCoV-19 vaccines and patients with confirmed COVID-19 and then measured S1 immunoglobulin (Ig) G and neutralizing antibodies and T-cell responses. RESULTS: A total of 121 vaccinees and 26 patients with confirmed COVID-19 were analyzed. After the second dose, the BNT162b2 vaccine yielded S1 IgG antibody responses similar to those achieved with natural infections (mean IgG titer [standard deviation], 2241 [899] vs 2601 [5039]; P = .68) but significantly stronger than responses to the ChAdOx1 vaccine (174 [96]; P < .001). The neutralizing antibody titer generated by BNT162b2 was 6-fold higher than that generated by ChAdOx1 but lower than that by natural infection. T-cell responses persisted for 3 months with BNT162b2 and natural infection but decreased with ChAdOx1. CONCLUSIONS: Antibody responses after the second dose of BNT162b2 are higher than after the second dose of ChAdOx1 and like those occurring after natural infection. T-cell responses are maintained longer in BNT162b2 vaccinees than in ChAdOx1 vaccinees.
SN - 1537-6613
UR - https://www.unboundmedicine.com/medline/citation/34850034/Immune_Responses_to_the_ChAdOx1_nCoV_19_and_BNT162b2_Vaccines_and_to_Natural_Coronavirus_Disease_2019_Infections_Over_a_3_Month_Period_
DB - PRIME
DP - Unbound Medicine
ER -
